Is TScan Therapeutics, Inc. (TCRX) a Buy, Sell, or Hold?
NASDAQ : TCRX
TScan Therapeutics, Inc.
$0.773 USD
$0.0 (-0.49%)
- Volume
- 523.99K
- Average Volume
- 829.65K
- Market Capitalization
- $47.21M
- P/E Ratio
- -0.85
- Dividend Yield
- 0.00%
- Price Target
- $7.50
- Year High
- $2.57
- Year Low
- $0.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.23
Company Overview
NASDAQ
Gavin MacBeath
Biotechnology
Healthcare
TCRX
139
US
USD
Liquidity Metrics
1.01
3.23
3.23
3.23
0.00
Sales & Valuation
$10.32M
6.64
1.46
-0.40
-0.91
Profitability
-$1
-$129.77M
-1655.35%
-1655.35%
-108.72%
-68.66%
P/E Metrics
-0.85
-0.05
-0.05
Analyst Price Target & Rating
$7.50
$12.00
$3.00
2/5
8 Analysts
-89.69%
Financial Health Scores
-4.70
2/9
$112.8M
$201.99M
$105.07M
-$121.53M
Key Metrics (TTM)
$11.92M
1.30
-0.10
6.65
-91.94%
-67.93%
-123.18%
-263.39%
-1213 days
Company Executives
| Name | Title |
|---|---|
| Chrystal U. Louis | Chief Medical Officer |
| Shrikanta Chattopadhyay | Senior Vice President & Head of Translational Medicine |
| Zoran Zdraveski | Chief Legal & Strategy Officer and Company Secretary |
| Jason A. Amello | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer |
| Jim Murray | Chief Development Operations Officer |
| Tomasz Kula | Co-Founder & Member of Advisory Board |
| Ann Hargraves | Chief Human Resources Officer |
| Gavin MacBeath | Chief Executive Officer & Director |
| Stephen J. Elledge | Co-Founder & Chairman of Scientific Advisory Board |
| Ray Lockard | Chief Manufacturing & Quality Officer |
Poll Results
No votes yet today — be the first to share your view!
About TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has ... a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn’s disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
2026-08-12 09:11:04
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-12 07:00:00
First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready manufacturing process Cash and cash equivalents fund operations into the second quarter of 2027 WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today reported financial results for the three months ended June 30, 2026, and provided a corporate update.
2026-07-29 07:00:00
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the first patient has been infused with TSC-101 in the pivotal Phase 3 ALLOHA-2™ trial (NCT07702578).
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-24 07:00:00
WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026 at 11:30 a.m. Eastern Time.
2026-06-22 07:00:00
11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101
2026-06-03 10:01:00
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology c
2026-06-03 09:19:00
SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced an agreement to evaluate automated clinical manufacturing of TSC-101, TScan's lead TCR-T therapy candidate for patients wit.
Frequently Asked Questions
-
What is the current TScan Therapeutics, Inc. (TCRX) stock price?
-
TScan Therapeutics, Inc.(NASDAQ:TCRX) stock price is $0.773 in the last trading session. During the trading session, TCRX stock reached the peak price of $2.57 while $0.716 was the lowest point it dropped to. The percentage change in TCRX stock occurred in the recent session was --0.49% while the dollar amount for the price change in TCRX stock was -$0.0.
-
TCRX's industry and sector of operation?
-
The NASDAQ listed TCRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TCRX?
-
Chrystal U. Louis | Chief Medical Officer
Shrikanta Chattopadhyay | Senior Vice President & Head of Translational Medicine
Zoran Zdraveski | Chief Legal & Strategy Officer and Company Secretary
Jason A. Amello | CFO, Treasurer, Principal Financial Officer & Principal Accounting Officer
Jim Murray | Chief Development Operations Officer -
How many employees does TCRX have?
-
Number of TCRX employees currently stands at 139. TCRX operates from 830 Winter Street, Waltham, MA 02451, US.
-
Link for TCRX official website?
-
Official Website of TCRX is: https://www.tscan.com
-
How do I contact TCRX?
-
TCRX could be contacted at phone #857 399 9500 and can also be accessed through its website. TCRX operates from 830 Winter Street, Waltham, MA 02451, US.
-
How many shares of TCRX are traded daily?
-
The average number of TCRX shares traded daily for last 3 months was 829.65K.
-
What is the market cap of TCRX currently?
-
The market value of TCRX currently stands at $47.21M with its latest stock price at $0.773